Text Size

Phase 2, randomized, dose-finding studies of omidenepag isopropyl, a selective EP2 agonist, in patients with primary open-angle glaucoma or ocular hypertension

Aihara M., Lu F., Kawata H., Iwata A., Liu K., Odani-Kawabata N., Shams N.K.

  • 2019
  • Journal of Glaucoma
View publication
  • Therapeutic Area


  • Categories

    Clinical development

  • Affiliations

    Department of Ophthalmology, University of Tokyo, Bunkyo-ku, Japan; Santen Pharmaceutical Co., Ltd., Osaka, Japan; Santen Inc., 6401 Hollis St Suite 125, Emeryville, CA 94608, United States

Related Publications

Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: 2-year Results from a Randomized, Multicenter Study

Panarelli JF, Moster MR, Garcia-Feijoo J, Flowers BE, Baker ND, Barnebey HS, Grover DS, Khatana AK, Lee B, Nguyen T, Stiles MC, Sadruddin O, Khaw PT.

Omidenepag Isopropyl in Latanoprost Low/Non-Responders with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3, Non-Randomized, Two-Phase, Open-Label Study

Panarelli JF, Bowden EC, Tepedino ME, Odani-Kawabata N, Pei Z, McLaurin EB, Ropo A.

The Development of a SIBS Shunt to Treat Glaucoma

Pinchuk L.

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022